A trial looking at zalutumumab with radiotherapy for head and neck cancer (GEN207)

We would like your feedback, please fill in our survey

Coronavirus (COVID-19)

We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.

Read about coronavirus and cancer

Cancer type:

Head and neck cancers

Laryngeal cancer

Mouth (oral) cancer

Status:

Results

Phase:

Phase 1/2

This trial was looking at zalutumumab with radiotherapy for cancer of the mouth or cancer of the voice box (larynx) that is locally advanced.

Doctors often treat locally advanced cancer of the mouth or cancer of the larynx with chemotherapy and radiotherapy together. They most often use platinum chemotherapy drugs Open a glossary item . But some people are not able to have platinum drugs.

Zalutumumab is a type of biological therapy called a monoclonal antibody. We knew from laboratory studies Open a glossary item that zalutumumab may stop or slow down the growth of cancer cells.

The aim of this trial was to find the maximum dose Open a glossary item of zalutumumab to use with radiotherapy.